CDSCO Approves First Indigenous mRNA Vaccine Platform for Tropical Diseases
Landmark Approval
The Central Drugs Standard Control Organisation (CDSCO) has granted conditional approval to India's first domestically developed mRNA vaccine platform, targeting dengue and chikungunya — two tropical diseases that collectively affect millions of Indians annually.
Development Journey
The platform was developed by a consortium of Indian biotech companies and academic institutions, building on the mRNA manufacturing capabilities established during the COVID-19 pandemic. Phase III trials enrolled over 15,000 participants across 12 states.
Clinical Trial Results
The dengue vaccine candidate showed 78.2% efficacy against symptomatic disease across all four serotypes, with a favorable safety profile. The chikungunya candidate demonstrated 84.5% efficacy in preventing clinical disease.
Written by
Dr. Priya Sharma
PharmD, PhD Clinical Pharmacology
Clinical pharmacologist with 10+ years of experience in drug safety evaluation. Currently a faculty member at NIPER Mohali.
Responses (1)
Log in to share your thoughts